CN106110182A - A kind of Chinese medicine composition treating cancer - Google Patents

A kind of Chinese medicine composition treating cancer Download PDF

Info

Publication number
CN106110182A
CN106110182A CN201610556241.3A CN201610556241A CN106110182A CN 106110182 A CN106110182 A CN 106110182A CN 201610556241 A CN201610556241 A CN 201610556241A CN 106110182 A CN106110182 A CN 106110182A
Authority
CN
China
Prior art keywords
cancer
chinese medicine
medicine composition
radix
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610556241.3A
Other languages
Chinese (zh)
Inventor
杨亚清
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610556241.3A priority Critical patent/CN106110182A/en
Publication of CN106110182A publication Critical patent/CN106110182A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/346—Platycodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/648—Myriapods, e.g. centipedes or millipedes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/65—Amphibians, e.g. toads, frogs, salamanders or newts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/074—Ganoderma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/344—Codonopsis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A61K36/428—Trichosanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/483—Gleditsia (locust)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/486—Millettia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/536—Prunella or Brunella (selfheal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/638—Ligustrum, e.g. Chinese privet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708—Rheum (rhubarb)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/744—Gardenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8966—Fritillaria, e.g. checker lily or mission bells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8994—Coix (Job's tears)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/902—Sparganiaceae (Bur-reed family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/904—Stemonaceae (Stemona family), e.g. croomia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Insects & Arthropods (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention discloses a kind of Chinese medicine composition treating cancer.Said composition is made up of 44 taste crude drug such as Radix Platycodonis, Radix Trichosanthis, Rhizoma Belamcandae, Rhizoma Paridis, Ganoderma, the Radix Stemonae, Spica Prunellae, Concha Ostreae, Sargassum, Radix Scutellariae, Fructus Gardeniae, Radix Actinidiae Chinensis, Radix Curcumae, Bulbus Fritillariae Thunbergii.Chinese medicine composition of the present invention adds customary adjuvant according to common process and makes capsule, tablet, pill, granule or the oral liquid of clinical acceptance.Pharmaceutical composition of the present invention can improve immunity of organisms, suppresses cancer cell growth, improves symptom, be greatly improved the life quality of cancer patient and extend its life cycle, and therapeutic effect is notable, has no adverse reaction.

Description

A kind of Chinese medicine composition treating cancer
Technical field
The present invention relates to a kind of pharmaceutical composition, particularly relate to a kind of Chinese medicine composition treating cancer.
Background technology
Cancer be body under various carcinogenic factor effects, it is right that some cell of local organization loses on gene level The normal regulation of its growth, causes its clonal abnormality hypertrophy and the neoplasm that formed, is to threaten healthy No.1 of modern killing Hands.The method treating cancer in prior art mainly uses chemotherapy and radiation, although both Therapeutic Method have certain curative effect, But, patient can feel the most painful during treating, and therefore, patient has the feared state of mind for both Therapeutic Method, unfavorable Treatment in disease.
At present, in most developed countries and China big city, when cancer patient goes to a doctor, majority is middle and advanced stage patient, often Lose optimal therapy apparatus meeting.How to improve the life quality of patient, extend the important class that life cycle is current treatment of cancer Topic.In China, the traditional Chinese medical science occupies critical role in terms for the treatment of cancer；Clinical and experimental study through decades proves: the traditional Chinese medical science Medicine can alleviate symptom and the chemotherapy side effect of cancer patient, has played important effect in terms of extending the survival of patients phase.
The technical problem to be solved in the present invention: a kind of Chinese medicine treating cancer is provided, especially treats breast carcinoma, cervical cancer Hepatocarcinoma, pulmonary carcinoma, gastric cancer, esophageal carcinoma, the brain cancer or nasopharyngeal carcinoma.This Chinese medicine can improve immunity of organisms, suppresses cancer cell growth, Improving symptom, be greatly improved the life quality of cancer patient and extend its life cycle, effect is obvious, has no adverse reaction.
Summary of the invention
Present invention aim at providing a kind of Chinese medicine composition treating cancer.
The present invention is achieved through the following technical solutions:
The crude drug of Chinese medicine composition of the present invention consists of:
The crude drug composition of Chinese medicine composition of the present invention is preferably:
The crude drug composition of Chinese medicine composition of the present invention is preferably:
The crude drug composition of Chinese medicine composition of the present invention is preferably:
Chinese medicine composition of the present invention adds customary adjuvant according to common process and makes the capsule of clinical acceptance, tablet, ball Agent, granule or oral liquid.
Chinese medicine composition of the present invention can improve immunity of organisms, suppresses cancer cell growth, improves symptom, be greatly improved The life quality of cancer patient also extends its life cycle, and therapeutic effect is notable, has no adverse reaction.
Experimental example is used for further illustrating the present invention below, but is not limited to the present invention.
Experimental example one: clinical trial
Clinical trial
1, clinical data
Add up breast carcinoma altogether, cervical cancer, hepatocarcinoma, pulmonary carcinoma, gastric cancer, esophageal carcinoma, the brain cancer, Nasopharyngeal Carcinoma Patients amount to 120 examples, year Age is 30-65 year.All cases are all through modern medicine pathology or cytolgical examination, the confirmation of CT and X sheet.Patient is the III phase Or IV phase cancer patient.
2, treatment situation: take oral liquid of the present invention (prepare according to embodiment 1 method, three times a day, each 1,10ml/ ), take 3 months.)
3, therapeutic outcome
MAIN OUTCOME MEASURES includes observing the cardinal symptom situation of change of cancer patient, life quality, situation life cycle, and Focus situation is observed by rabat before and after treatment and CT examination result.
4, cardinal symptom change: take the cancer patient after oral liquid of the present invention (preparing according to embodiment 1 method) 3, Mental status is clearly better, cough, chest pain, mastalgia, uncomfortable in chest, breathe hard, expectorant blood also takes an evident turn for the better or disappears, cancer-free cell shift Situation.
5, body weight change: patient receives to eat and takes on a new look greatly, all has body weight in various degree to increase.
6, existence treatment evaluation change: according to Karnofsky activity situation grade scale, compare with the situation before treatment, Increasing by 10 after treatment and be divided into increase, reduce 10 and be divided into decline, change is divided into stable less than 10.As a result, enhancer 100 example, under Fall person 1 example, the person of stablizing 19 example.
7, short term effect evaluation: according in December, 1978 Changzhou meeting " the anticancer curative effect of medication universal standard ", to 120 examples Before and after patient, situation has made comparison, shows: checking CT, X sheet after treating three months, the focus of patient all has different situation not Deng improvement, life quality is greatly improved, and pain is logical the most substantially to be alleviated, and cancerous cell is without transfer.
8, medical record citing:
Zhao's ××, female, age of onset 61 years old, found during patient bath before 1 year that left breast has an enclosed mass, check really through provincial hospital Examining " breast carcinoma ", handled and be in hospital, this plan excision breast, patient was afraid at heart later, abandoned operation.Take upon somebody's introduction With oral liquid of the present invention (preparing according to embodiment 1 method), after two months, enclosed mass is obviously reduced, enclosed mass after continuing to take 1 month Without.Following up a case by regular visits to after 3 years, health is without exception, and solarization of going out every day is got sun, and chats with age cohorts, health, life, mental attitude Deng the best.
Poplar ××, man 56 years old, retired professor, it is diagnosed as peripheral type carcinoma of lung through CT, X sheet, B ultrasonic in November, 2008,2009 years 1 The moon takes oral liquid of the present invention (preparing according to embodiment 1 method).Shallow complexion during patient assessment, cough and asthma, spirit is poor, disappears Thin, diet is the best, light red tongue, and deep-rolling pulse is thin.Treatment: taking oral liquid of the present invention, three times a day, each 1,10ml/ props up, clothes After 1 month, spirit is taken on a new look, and health is strong, and appetite increases.Continuing to take after two months, cough and asthma is substantially alleviated, and spirit is bright Aobvious improvement, pain disappears substantially.Follow up a case by regular visits to after 1 year also be still living and in good health.
Two, pharmacodynamics test
(1) ordinary circumstance
Medicine of the present invention (preparing according to embodiment 1 method) has supplementing QI and nourishing YIN, changes the function of eliminating stagnation, for cancer gas Deficiency of YIN, the medicine of the auxiliary treatment of phlegm and blood stasis disease.Function according to this medicine cures mainly feature, according to the requirement of hospital preparation, Employing eliminating pathogenic factor for supporting vital QI is main experimental, verifies the function of this medicine and cures mainly.According to the model feature in the testing program determined, choosing With positive control medicine cyclophosphamide.
The determination of dosage: draw with dosage reckoning according to clinical people.Empirically animals and human beings body surface area compares dose,equivalent Calculate and obtain than table conversion.Adult's consumption every day is 1/time, and 3 times/day, 10ml/ props up, and therefore, dosage used by every day of being grown up is 30ml.By table calculate mice dose,equivalent with 1 and 2 times and 4 times amount be set to basic, normal, high dosage group: 3ml/kg, 6ml/kg, 12ml/kg.Clinical administration approach is oral, and therefore mice is administered and is also administered for oral administration gavage, successive administration 10 days.
Material
1, test medicine:
Medicine of the present invention (is prepared according to embodiment 1 method), is made into suspension (0.5%CMC-with sodium carboxymethyl cellulose Na), the used time is configured to desired concn, 4 DEG C of Refrigerator stores.
2, positive control drug:
Cyclophosphamide: sino-america joint-venture Shanxi Tai Sheng pharmaceutical Co. Ltd, lot number: 000906, the used time is made into institute with distilled water Need concentration, matching while using, experiment selects 30mg/kg, lumbar injection, the next day be administered, totally 5 times.
3, animal:
ICR mice: two grades, 18～22g, male and female (but every batch is selected same sex), purchased from the experiment of Beijing dimension tonneau China Zoo technical company limited.
C57BL/6 mice: two grades, 18-22, male and female (but every batch is selected same sex), purchased from China Medical institute animal Institute.
4, tumor strain:
Mice Bearing Lewis Lung Cancer: provided by China Medical institute medicine institute's cancer room.
Rat liver cancer: provided by China Medical institute medicine institute's cancer room.
Mouse Gastric Cancer: provided by China Medical institute medicine institute's cancer room.
Mouse Esophageal cancer: provided by China Medical institute medicine institute's cancer room.
Mouse breast cancer: provided by China Medical institute medicine institute's cancer room.
Mouse cervical cancer: provided by China Medical institute medicine institute's cancer room.
The mice brain cancer: provided by China Medical institute medicine institute's cancer room.
Mice nasopharyngeal carcinoma: provided by China Medical institute medicine institute's cancer room.
5, reagent:
India ink: Beijing No.4 Middle School chemical plant, lot number: 820501.Used time is with normal saline dilution 10 times.
6, instrument:
Ultraviolet spectrophotometer: Japan's Shimadzu UV-1601PC
Centrifuge: LXJ-II type, numbering 6260, Shanghai medical analytical instrument factory
Precise electronic analytical balance: EB-280M-22 type, KYOTO company of Japan
Microplate reader: DG-3022A type East China Electronics Co., Ltd instrument plant
Method and result
(2), the foundation of animal model
1, rat liver cancer cancer model
Pass on hepatocarcinoma tumor strain in 7 days in mouse peritoneal, after aseptic taking-up, with brine 2 times, count and adjust cell to arrive 1×107Individual/ml, and be inoculated in mouse peritoneal, it is 0.2ml that every Mus inoculates above-mentioned cell suspension.
2, mice lung cancer model
Selecting inoculation about 7 days well-growns of Lewis lung cancer in oxter without the mice of ulceration, dislocation is put to death, fixing, with ethanol, Iodine disinfection skin, peels off cancer, and cancer external fat and tissue is rejected, weighing, add in 1: 4 ratio raw under aseptic condition Reason saline, grinds to form cell suspension with dismembyator, counts and adjust cell to 1 × 107Individual/ml, and it is subcutaneous to be inoculated into the right axil of mice, It is 0.2ml that every Mus inoculates above-mentioned cell suspension.
3, Mouse Gastric Cancer model
Pass on gastric cancer tumor strain in 7 days in mouse peritoneal, after aseptic taking-up, with brine 2 times, count and adjust cell to arrive 1×107Individual/ml, and be inoculated in Mouse Stomach, it is 0.2ml that every Mus inoculates above-mentioned cell suspension.
4, Mouse Esophageal cancer model
Pass on esophagus carcinoma strain in 7 days in mouse peritoneal, after aseptic taking-up, with brine 2 times, count and adjust cell To 1 × 107Individual/ml, and be inoculated in Mouse Esophageal, it is 0.2ml that every Mus inoculates above-mentioned cell suspension.
5, mouse breast cancer
Pass on breast malignant tumor strain in 7 days in mouse peritoneal, after aseptic taking-up, with brine 2 times, count and adjust cell To 1 × 107Individual/ml, and be inoculated in mouse peritoneal, it is 0.2ml that every Mus inoculates above-mentioned cell suspension.
6, mouse cervical cancer model
Pass on cervical cancer tumor strain in 7 days in mouse peritoneal, after aseptic taking-up, with brine 2 times, count and adjust cell To 1 × 107Individual/ml, and be inoculated in mouse peritoneal, it is 0.2ml that every Mus inoculates above-mentioned cell suspension.
7, mice brain cancer model
Pass on brain cancer tumor strain in 7 days in mouse brain, after aseptic taking-up, with brine 2 times, count and adjust cell to arrive 1×107Individual/ml, and be inoculated in mouse brain, it is 0.2ml that every Mus inoculates above-mentioned cell suspension.
8, mice rhinopharyngocele cancer model
Mice intranasal passes on nasopharynx carcinoma strain in 7 days, after aseptic taking-up, with brine 2 times, counts and adjusts cell to arrive 1×107Individual/ml, and it is inoculated into mice nasal cavity, it is 0.2ml that every Mus inoculates above-mentioned cell suspension.
(3), the inhibitory action to Murine cancer
Take above-mentioned 8 groups of mouse models, the most male C57BL/6 mice, the respectively right above-mentioned cancer cell of axil subcutaneous vaccination 0.2ml, is randomly divided into 5 groups after 24 hours, often group 16 (8 groups mouse model each 2), and blank group gavage is given and waited capacity 0.5% CMC-Na；Positive control cyclophosphamide, lumbar injection 30mg/kg, (administration time is the 1st day, 3 days, 5 days, 7 days, 9 days)；This Invention medicine high, medium and low dosage group gastric infusion, once a day, continuous 10 days.After drug withdrawal, dislocation in 24 hours is put to death, and weighs Body weight, tumor weight, thymus, spleen weight (calculating thymus and index and spleen index).
Calculate growth of cancers suppression ratio=(C-T)/C × 100%
T: experimental group average weight C: matched group average tumor weight, above experiment is repeated 2 times (totally 3 batches).
Result shows, the continuous gastric infusion of medicine of the present invention 10 days, repeats three batches of tumour inhibiting rate high doses respectively: 38.38, 52.82,43.45%；Middle dosage group is 33.33,40.51,32.46%；Low dose group is 23.23,33.85,15.18%, and There is a certain amount effect relationship.Dosage group high, middle has the effect (P significantly suppressing growth of cancers to mice transplantability cancer ＜ 0.01).
(4), survival time of mice is affected
Taking above-mentioned 8 groups of mouse models, the most male C57BL/6, every mouse peritoneal injects 0.2ml EAC oncocyte, 5 groups it are randomly divided into, often group 16 (8 groups mouse model each 2) after 24 hours.Blank group is given and is waited capacity 0.5%CMC-Na； Positive control cyclophosphamide lumbar injection 30mg/kg；Medicine of the present invention high, medium and low dosage group gastric infusion, once a day, even Continuous 10 days.Drug withdrawal in 11st day, later every day observed and recorded dead mouse situation record, result calculates Bearing Mice Life Prolongation rate.
Increase in life span=(T-C)/C × 100%
T: experimental group the average survival time natural law C: more than matched group the average survival time natural law test and be repeated 2 times (totally 3 batches).
Result shows, the continuous gastric infusion of medicine of the present invention 10 days, repeats three batches, and each dosage group the most significantly extends mice The life cycle of EAC ascitic type cancer, high dose group is respectively 34.54,65.54,69.40%；Middle dosage component is not 46.47, 64.22,103.62%；Low dose group is respectively 43.55,26.57,85.18%.Result shows, each dosage group is obviously prolonged EAC Ascitic type cancer survival time of mice, each group average life rate elongation is all higher than 50%.
(5), the analgesic activity to mice
Taking above-mentioned 8 groups of mouse models, the most male C57BL/6 mice is each, is divided into 5 groups, often 16 (7 groups of mice moulds of group Each 2 of type).Matched group is given and is waited capacity 0.5%CMC-Na, positive drug indomethacin；Medicine of the present invention high, medium and low dosage group.With Upper each group of equal gastric infusion, after being administered 1 mice, each Mus equal lumbar injection 0.6% acetic acid 0.2ml/ is only.Each Mus in observing 15 minutes The writhing response number of times occurred.
Result shows: medicine of the present invention has obvious analgesic activity, and has obvious dose-effect relationship, dosage group high, middle Compare with matched group and have significant difference (P ＜ 0.05-0.001).
The analgesic activity (X ± S) of Dichlorodiphenyl Acetate writhing response
Group dosage (mg/kg) Number of animals (only) There is number of animals (only) in writhing Writhing response number of times
Blank group 10 10 30.15±11.65
Indomethacin 10 10 30.82±0.58***
High dose 800 10 9 13.82±8.68**
Middle dosage 400 10 10 16.89±7.89**
Low dosage 200 10 10 25.86±10.58
Note: compare * * P ＜ 0.01, * * * P ＜ 0.001 with blank group.
Following embodiment all can realize the effect of above-mentioned experimental example.
Detailed description of the invention
Embodiment 1 oral liquid
Said medicine according to common process add customary adjuvant make oral liquid, 10ml/ props up, three times on the one, one time 1.
Embodiment 2 pill
Said medicine adds customary adjuvant according to common process and makes the watered pill, 6g/ bag, three times on the one, one time 1 bag.
Embodiment 3 capsule
Said medicine adds customary adjuvant according to common process and makes capsule.0.3g/ grain, three times a day, each two.
Embodiment 4 tablet
Said medicine adds customary adjuvant according to common process and makes tablet.0.3g/ sheet, three times a day, each two.
Embodiment 5 granule
Said medicine adds customary adjuvant according to common process and makes granule, every bag of 6g, three times on the one, one time 1 bag.

Claims (7)

1. the Chinese medicine composition treating cancer, it is characterised in that the crude drug of said composition consists of:
2. Chinese medicine composition as claimed in claim 1, it is characterised in that the crude drug of said composition consists of:
3. Chinese medicine composition as claimed in claim 1, it is characterised in that the crude drug of said composition consists of:
4. Chinese medicine composition as claimed in claim 1, it is characterised in that the crude drug of said composition consists of:
5. the Chinese medicine composition as described in one of claim 1-4, it is characterised in that said composition often adds according to common process Capsule, tablet, pill, granule or the oral liquid of clinical acceptance made by rule adjuvant.
6. the application in the medicine of preparation treatment cancer of the Chinese medicine composition as described in one of claim 1-4.
7. the Chinese medicine composition as claimed in claim 6 application in the medicine of preparation treatment cancer, wherein said cancer is Refer to breast carcinoma, cervical cancer, hepatocarcinoma, pulmonary carcinoma, gastric cancer, esophageal carcinoma, the brain cancer or nasopharyngeal carcinoma.
CN201610556241.3A 2016-06-30 2016-06-30 A kind of Chinese medicine composition treating cancer Pending CN106110182A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610556241.3A CN106110182A (en) 2016-06-30 2016-06-30 A kind of Chinese medicine composition treating cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610556241.3A CN106110182A (en) 2016-06-30 2016-06-30 A kind of Chinese medicine composition treating cancer

Publications (1)

Publication Number Publication Date
CN106110182A true CN106110182A (en) 2016-11-16

Family

ID=57283958

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610556241.3A Pending CN106110182A (en) 2016-06-30 2016-06-30 A kind of Chinese medicine composition treating cancer

Country Status (1)

Country Link
CN (1) CN106110182A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111437359A (en) * 2019-01-17 2020-07-24 杭州市第三人民医院 Application of traditional Chinese medicine composition containing astragalus in regulating and controlling gastric cancer immune microenvironment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102357180A (en) * 2011-10-24 2012-02-22 成都恩威投资（集团）有限公司 Traditional Chinese medicine composite for curing cancer and preparation method and application thereof
CN105688147A (en) * 2016-02-27 2016-06-22 吴风平 Traditional Chinese medicine composition for treating tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102357180A (en) * 2011-10-24 2012-02-22 成都恩威投资（集团）有限公司 Traditional Chinese medicine composite for curing cancer and preparation method and application thereof
CN105688147A (en) * 2016-02-27 2016-06-22 吴风平 Traditional Chinese medicine composition for treating tumors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111437359A (en) * 2019-01-17 2020-07-24 杭州市第三人民医院 Application of traditional Chinese medicine composition containing astragalus in regulating and controlling gastric cancer immune microenvironment

Similar Documents

Publication Publication Date Title
CN105816623A (en) Probiotic fermented traditional Chinese medicinal compound composition for treating and improving metabolic syndrome, and preparation method and application thereof
CN102600212A (en) Medicinal health product for immunity enhancement and adjuvant treatment of tumor
CN100593417C (en) Chinese traditional medicine for treating gastric cancer and bone cancer
CN102579803B (en) Medicine for treating post-chemotherapy leucopenia and preparation method thereof
CN105688147A (en) Traditional Chinese medicine composition for treating tumors
CN102028924B (en) Medicinal composition for late gastric cancer
CN101999655B (en) Biotransformation functional food and producing method thereof
CN106110182A (en) A kind of Chinese medicine composition treating cancer
CN102755600A (en) Traditional Chinese medicine compound for resisting breast cancer metastasis and reoccurrence
CN101647962A (en) Traditional Chinese medicine preparation for curing depression
CN101461894A (en) Medicament composition for treating female climacteric syndrome and delaying age
CN103636875A (en) Anti-cancer herbal tea
CN102091155B (en) Traditional Chinese medicine preparation for preventing and treating fatigue due to sub-health
CN103239470A (en) Dual-mushroom polysaccharide composition containing coprinus comatus polysaccharide and lentinan as well as preparation method and application thereof
CN102805799A (en) Traditional Chinese medicine composition with antitumous effect
CN107019771A (en) A kind of antineoplastic Chinese medicine composition
CN106039065A (en) Traditional Chinese medicine composition for treating tumors
CN105878851A (en) Pharmaceutical composition for treating qi-blood deficiency syndrome and preparation method of pharmaceutical composition
CN103908622A (en) Application of Buyi Zisheng pill in preparation of drug used for treating depression
CN103948666B (en) Preparation method of Tibetan medicine for treating diabetes
CN116327857B (en) Traditional Chinese medicine composition for treating malignant peritoneal effusion as well as preparation method and application thereof
CN1211110C (en) Chinese medicine composition for treating tumour
CN111920874B (en) A Chinese medicinal buccal pill for treating middle and late stage esophageal cancer
CN103191267A (en) Traditional Chinese medicine composition for treating liver cancers
CN102836315A (en) Chinese medicinal composition for preventing and conditioning prognosis tumors and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20161116